NUT Midline Carcinoma of the Head and Neck: A Systematic Review and Pooled Survival Analysis.

Head NeckMay 22, 2026 (epub)
Clinical ResearchOncology (Medical)Pathology (Anatomic & Clinical)

Michelle Yoon, Ricardo Ramirez, Harrison Smith et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

NUT midline carcinoma (NMC) is an aggressive malignancy driven by NUTM1 fusions in poorly differentiated tumor cells. This pooled analysis evaluates the impact of primary tumor location on overall survival (OS) in head and neck (HN) NMC.

Reported results

Of 261 screened articles, 81 met inclusion criteria. Overall, 138 cases were included in demographic analyzes and 65 in survival analyzes. Tracheo-laryngopharyngeal tumors trended toward worse OS (HR 2.45, 95% CI 1.01-5.95, p = 0.047). Orbito-sinonasal tumors trended toward improved OS (HR 0.75, 95% CI 0.46-1.24, p = 0.25). BRD4-NUTM1 fusions were associated with worse OS (HR 8.3, 95% CI 4.26-16.23, p = 0.0003).

Authors' conclusions

HN NMC carries a poor prognosis, and BRD4-NUTM1 fusions have worse outcomes. Primary subsite is a potential prognostic variable that may inform future studies.

Source

PubMed · PMID 42175568

Published in Head Neck. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.